(Lithocarpus Polystachyus Rehd.) Based Upon Location, Harvesting Time, Leaf Age
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Natural Products As Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
Reviews Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors Author ABSTRACT Wolfgang Blaschek Glucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon as well as by regulation of glu- Affiliation cose absorption, gluconeogenesis, biosynthesis and mobiliza- Formerly: Institute of Pharmacy, Department of Pharmaceu- tion of glycogen, glucose consumption in all tissues and glo- tical Biology, Christian-Albrechts-University of Kiel, Kiel, merular filtration, and reabsorption of glucose in the kidneys. Germany Glucose enters or leaves cells mainly with the help of two membrane integrated transporters belonging either to the Key words family of facilitative glucose transporters (GLUTs) or to the Malus domestica, Rosaceae, Phlorizin, flavonoids, family of sodium glucose cotransporters (SGLTs). The intesti- ‑ SGLT inhibitors, gliflozins, diabetes nal glucose absorption by endothelial cells is managed by SGLT1, the transfer from them to the blood by GLUT2. In the received February 9, 2017 kidney SGLT2 and SGLT1 are responsible for reabsorption of revised March 3, 2017 filtered glucose from the primary urine, and GLUT2 and accepted March 6, 2017 GLUT1 enable the transport of glucose from epithelial cells Bibliography back into the blood stream. DOI http://dx.doi.org/10.1055/s-0043-106050 The flavonoid phlorizin was isolated from the bark of apple Published online April 10, 2017 | Planta Med 2017; 83: 985– trees and shown to cause glucosuria. Phlorizin is an inhibitor 993 © Georg Thieme Verlag KG Stuttgart · New York | of SGLT1 and SGLT2. With phlorizin as lead compound, specif- ISSN 0032‑0943 ic inhibitors of SGLT2 were developed in the last decade and some of them have been approved for treatment mainly of Correspondence type 2 diabetes. -
Myricetin Antagonizes Semen-Derived Enhancer of Viral Infection (SEVI
Ren et al. Retrovirology (2018) 15:49 https://doi.org/10.1186/s12977-018-0432-3 Retrovirology RESEARCH Open Access Myricetin antagonizes semen‑derived enhancer of viral infection (SEVI) formation and infuences its infection‑enhancing activity Ruxia Ren1,2†, Shuwen Yin1†, Baolong Lai2, Lingzhen Ma1, Jiayong Wen1, Xuanxuan Zhang1, Fangyuan Lai1, Shuwen Liu1* and Lin Li1* Abstract Background: Semen is a critical vector for human immunodefciency virus (HIV) sexual transmission and harbors seminal amyloid fbrils that can markedly enhance HIV infection. Semen-derived enhancer of viral infection (SEVI) is one of the best-characterized seminal amyloid fbrils. Due to their highly cationic properties, SEVI fbrils can capture HIV virions, increase viral attachment to target cells, and augment viral fusion. Some studies have reported that myri- cetin antagonizes amyloid β-protein (Aβ) formation; myricetin also displays strong anti-HIV activity in vitro. Results: Here, we report that myricetin inhibits the formation of SEVI fbrils by binding to the amyloidogenic region of the SEVI precursor peptide (PAP248–286) and disrupting PAP248–286 oligomerization. In addition, myricetin was found to remodel preformed SEVI fbrils and to infuence the activity of SEVI in promoting HIV-1 infection. Moreover, myricetin showed synergistic efects against HIV-1 infection in combination with other antiretroviral drugs in semen. Conclusions: Incorporation of myricetin into a combination bifunctional microbicide with both anti-SEVI and anti- HIV activities is a highly promising approach to preventing sexual transmission of HIV. Keywords: HIV, Myricetin, Amyloid fbrils, SEVI, Synergistic antiviral efects Background in vivo because they facilitate virus attachment and inter- Since the frst cases of acquired immune defciency nalization into cells [4]. -
Defective Galactose Oxidation in a Patient with Glycogen Storage Disease and Fanconi Syndrome
Pediatr. Res. 17: 157-161 (1983) Defective Galactose Oxidation in a Patient with Glycogen Storage Disease and Fanconi Syndrome M. BRIVET,"" N. MOATTI, A. CORRIAT, A. LEMONNIER, AND M. ODIEVRE Laboratoire Central de Biochimie du Centre Hospitalier de Bichre, 94270 Kremlin-Bicetre, France [M. B., A. C.]; Faculte des Sciences Pharmaceutiques et Biologiques de I'Universite Paris-Sud, 92290 Chatenay-Malabry, France [N. M., A. L.]; and Faculte de Midecine de I'Universiti Paris-Sud et Unite de Recherches d'Hepatologie Infantile, INSERM U 56, 94270 Kremlin-Bicetre. France [M. 0.1 Summary The patient's diet was supplemented with 25-OH-cholecalci- ferol, phosphorus, calcium, and bicarbonate. With this treatment, Carbohydrate metabolism was studied in a child with atypical the serum phosphate concentration increased, but remained be- glycogen storage disease and Fanconi syndrome. Massive gluco- tween 0.8 and 1.0 mmole/liter, whereas the plasma carbon dioxide suria, partial resistance to glucagon and abnormal responses to level returned to normal (18-22 mmole/liter). Rickets was only carbohydrate loads, mainly in the form of major impairment of partially controlled. galactose utilization were found, as reported in previous cases. Increased blood lactate to pyruvate ratios, observed in a few cases of idiopathic Fanconi syndrome, were not present. [l-14ClGalac- METHODS tose oxidation was normal in erythrocytes, but reduced in fresh All studies of the patient and of the subjects who served as minced liver tissue, despite normal activities of hepatic galactoki- controls were undertaken after obtaining parental or personal nase, uridyltransferase, and UDP-glucose 4epirnerase in hornog- consent. enates of frozen liver. -
Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative
Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative Chemical Dosage (+)-BORNYL-ISOVALERATE -- (-)-DICENTRINE LD50=187 1,8-CINEOLE -- 2-METHYLBUT-3-ENE-2-OL -- 6-GINGEROL -- 6-SHOGAOL -- ACYLSPINOSIN -- ADENOSINE -- AKUAMMIDINE -- ALPHA-PINENE -- ALPHA-TERPINEOL -- AMYL-BUTYRATE -- AMYLASE -- ANEMONIN -- ANGELIC-ACID -- ANGELICIN ED=20-80 ANISATIN 0.03 mg/kg ANNOMONTINE -- APIGENIN 30-100 mg/kg ARECOLINE 1 mg/kg ASARONE -- ASCARIDOLE -- ATHEROSPERMINE -- BAICALIN -- BALDRINAL -- BENZALDEHYDE -- BENZYL-ALCOHOL -- Chemical Dosage BERBERASTINE -- BERBERINE -- BERGENIN -- BETA-AMYRIN-PALMITATE -- BETA-EUDESMOL -- BETA-PHENYLETHANOL -- BETA-RESERCYCLIC-ACID -- BORNEOL -- BORNYL-ACETATE -- BOSWELLIC-ACID 20-55 mg/kg ipr rat BRAHMINOSIDE -- BRAHMOSIDE -- BULBOCAPNINE -- BUTYL-PHTHALIDE -- CAFFEIC-ACID 500 mg CANNABIDIOLIC-ACID -- CANNABINOL ED=200 CARPACIN -- CARVONE -- CARYOPHYLLENE -- CHELIDONINE -- CHIKUSETSUSAPONIN -- CINNAMALDEHYDE -- CITRAL ED 1-32 mg/kg CITRAL 1 mg/kg CITRONELLAL ED=1 mg/kg CITRONELLOL -- 2 Chemical Dosage CODEINE -- COLUBRIN -- COLUBRINOSIDE -- CORYDINE -- CORYNANTHEINE -- COUMARIN -- CRYOGENINE -- CRYPTOCARYALACTONE 250 mg/kg CUMINALDEHYDE -- CUSSONOSIDE-A -- CYCLOSTACHINE-A -- DAIGREMONTIANIN -- DELTA-9-THC 10 mg/orl/man/day DESERPIDINE -- DESMETHOXYANGONIN 200 mg/kg ipr DIAZEPAM 40-200 ug/lg/3-4x/day DICENTRINE LD50=187 DIDROVALTRATUM -- DIHYDROKAWAIN -- DIHYDROMETHYSTICIN 60 mg/kg ipr DIHYDROVALTRATE -- DILLAPIOL ED50=1.57 DIMETHOXYALLYLBENZENE -- DIMETHYLVINYLCARBINOL -- DIPENTENE -
Objectives Anti-Hyperglycemic Therapeutics
9/22/2015 Some Newer Non-Insulin Therapies for Type 2 Diabetes:Present and future Faculty/presenter disclosure Speaker’s name: Dr. Robert G. Josse SGLT2 Inhibitors Grants/research support: Astra Zeneca, BMS, Boehringer Dopamine D2 Receptor Agonist Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Roche, Bile acid sequestrant sanofi, Consulting Fees: Astra Zeneca, BMS, Eli Lilly, Janssen, Merck, Dr Robert G Josse Division of Endocrinology & Metabolism Speakers bureau: Janssen, Astra Zeneca, BMS, Merck, St. Michael’s Hospital Professor of Medicine Stocks and Shares:None University of Toronto 100-year History of Objectives Anti-hyperglycemic Therapeutics 14 Discuss the mechanism of action of SGLT2 inhibitors, SGLT-2 inhibitor 12 Bromocriptine-QR dopamine D2 receptor agonists and bile acid sequestrants Bile acid sequestrant in the management of type 2 diabetes Number of 10 DPP-4 inhibitor classes of GLP-1 receptor agonist Amylinomimetic anti- 8 Glinide Basal insulin analogue Identify the benefits and risks of the newer non-insulin hyperglycemic Thiazolidinedione agents 6 Alpha-glucosidase inhibitor treatment options Phenformin Human Rapid-acting insulin analogue 4 Sulphonylurea insulin Metformin Intermediate-acting insulin Phenformin Describe the potential uses of these therapies in the 2 withdrawn Soluble insulin treatment of type 2 diabetes 0 1920 1940 1960 1980 2000 2020 Year UGDP, DCCT and UKPDS studies. Buse, JB © 1 9/22/2015 Renal handling of glucose Collecting (180 L/day) Glomerulus duct (1000 mg/L) Proximal =180 g/day Distal tubule S1 tubule Glucose ~90% filtration SGLT2 Inhibitors ~10% S3 Glucose reabsorption Loop No/minimal of Henle glucose excretion S1 segment of proximal tubule S3 segment of proximal tubule - ~90% glucose reabsorbed - ~10% glucose reabsorbed - Facilitated by SGLT2 - Facilitated by SGLT1 SGLT = Sodium-dependent glucose transporter Adapted from: 1. -
The Dietary Phytochemical Myricetin Induces Ros-Dependent Breast Cancer Cell Death
THE DIETARY PHYTOCHEMICAL MYRICETIN INDUCES ROS-DEPENDENT BREAST CANCER CELL DEATH by Allison F. Knickle Submitted in partial fulfilment of the requirements for the degree of Master of Science at Dalhousie University Halifax, Nova Scotia December 2014 © Copyright by Allison F. Knickle, 2014 Table of Contents List of Figures ....................................................................................................... iv List of Tables ........................................................................................................ vi Abstract ................................................................................................................ vii List of Abbreviations and Symbols Used ............................................................. viii Acknowledgements ............................................................................................. xiii CHAPTER 1 INTRODUCTION ............................................................................. 1 1.1. Cancer ...................................................................................................................... 1 1.2 Breast Cancer ........................................................................................................... 1 1.2.1 Triple-negative breast cancer .............................................................................. 3 1.3 Cell death .................................................................................................................. 4 1.3.1 Apoptosis ............................................................................................................ -
Phytochemistry / Fitoquímica
Botanical Sciences 98(4): 545-553. 2020 Received: April 20, 2020, Accepted: July 25, 2020 DOI: 10.17129/botsci.2624 On line first: October 12, 2020 Phytochemistry / Fitoquímica BIOLOGICAL ACTIVITY AND FLAVONOID PROFILE OF FIVE SPECIES OF THE BURSERA GENUS ACTIVIDAD BIOLÓGICA Y PERFIL DE FLAVONOIDES DE CINCO ESPECIES DEL GÉNERO BURSERA ID MA. BEATRIZ SÁNCHEZ-MONROY1, ID ANA MARÍA GARCÍA-BORES2, ID JOSÉ LUIS CONTRERAS-JIMÉNEZ 3, ID DAVID EDUARDO TORRES1, ID RUBÉN SAN MIGUEL-CHÁVEZ4, ID PATRICIA GUEVARA-FEFER1* 1Departamento de Ecología y Recursos Naturales. Facultad de Ciencias. Universidad Nacional Autónoma de México. Ciudad de México, Mexico. 2Laboratorio de Fitoquímica, UBIPRO, Facultad de Estudios Superiores-Iztacala. Universidad Nacional Autónoma de México, Tlalnepantla, Mexico. 3Benemérita Universidad Autónoma de Puebla, Puebla, Mexico. 4Laboratorio de Fitoquímica, Colegio de Postgraduados, Montecillo, CP 56230, Estado de México, Mexico. *Author for correspondence: [email protected] Abstract Background: The genus Bursera Jacq. ex. L. concentrates its diversity in Mexico. Among the secondary metabolites that can be isolated from organic its extracts are flavonoids and lignans. Research question: Do the biological activity of the hydroalcoholic extracts from five Bursera species studied depend on their flavonoid content? Study site: Oaxaca, Mexico. Methods: The extracts of B. aptera Ramírez, B. fagaroides (Kunth) Engl., B. schlechtendalii Engl., B. galeottiana Engl., B. morelensis Ramírez were analysed by High Resolution Liquid Chromatography (HPLC) to determine their flavonoid composition. The antiradical DPPH, anti-inflammatory, antibacterial and antifungal activities of the extracts were determined. Results: Phlorizin and quercetin were conserved in both stems and leaves of the five species studied. The phloretin was present only in the leaves of B. -
Isolation of Kaempferol Glycosides from Ginkgo Biloba Leaves and Synthesis, Identification and Quantification of Their Major in Vivo Metabolites
Isolation of Kaempferol Glycosides from Ginkgo biloba Leaves and Synthesis, Identification and Quantification of their major in vivo Metabolites DISSERTATION ZUR ERLANGUNG DES DOKTORGRADES DER NATURWISSENSCHAFTEN (DR. RER. NAT.) DER NATURWISSENSCHAFTLICHEN FAKULTÄT IV DER UNIVERSITÄT REGENSBURG vorgelegt von Daniel Bücherl aus Dieterskirchen 2013 Die vorliegende Arbeit entstand im Zeitraum vom März 2010 bis Oktober 2013 unter der Leitung von Herrn Prof. Dr. Jörg Heilmann am Lehrstuhl für Pharmazeutische Biologie am Institut für Pharmazie der Naturwissenschaflichen Fakultät IV – Chemie und Pharmazie – der Universität Regensburg. Das Promotionsgesuch wurde eingereicht im Oktober 2013 Tag der mündlichen Prüfung: 29.11.2013 Prüfungsausschuss: Prof. Dr. Gerhard Franz (Vorsitzender) Prof. Dr. Jörg Heilmann (Erstgutachter) Prof. Dr. Joachim Wegener (Zweitgutachter) Prof. Dr. Frank-Michael Matysik (Drittprüfer) Was du für den Gipfel hältst, ist nur eine Stufe. Lucius Annaeus Seneca Danksagung Ein großes Dankeschön geht an alle die mir während meiner Promotion hilfreich zur Seite gestanden haben. Besonders möchte ich danken: Prof. Dr. Jörg Heilmann für das Vertrauen und die Möglichkeit mir dieses interessante Projekt zu überlassen, für zahlreiche wertvolle Diskussionen und für die lehrreiche und schöne Zeit in seiner Arbeitsgruppe; Dr. Egon Koch und Dr. Clemens Erdelmeier der Dr. Willmar Schwabe GmbH und Co. KG, für die Mitbetreuung dieser Arbeit, ihre zahlreichen wertvollen Beiträge, die hilfreichen Diskussionen, die Bereitstellung der Flavonoidfraktionen von EGb 761®, und die Durchführung der Fütterungsexperimente an den Ratten; Dr. Willmar Schwabe GmbH und Co. KG für die grosszügige finanzielle Unterstützung dieser Arbeit; meinen Kolleginnen und Kollegen am Lehrstuhl für Pharmazeutische Biologie sowie auch allen Praktikanten, für die freundliche Aufnahme in der Gruppe, das wunderbare Arbeitsklima und ihre Hilfsbereitsschaft. -
Coffea Arabica Bean Extract Inhibits Glucose Transport and Disaccharidase Activity in Caco‑2 Cells
BIOMEDICAL REPORTS 15: 73, 2021 Coffea arabica bean extract inhibits glucose transport and disaccharidase activity in Caco‑2 cells ATCHARAPORN ONTAWONG1, ACHARAPORN DUANGJAI1 and CHUTIMA SRIMAROENG2 1Division of Physiology, School of Medical Sciences, University of Phayao, Muang Phayao, Phayao 56000; 2Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Nong Khai 52000, Thailand Received February 3, 2021; Accepted June 14, 2021 DOI: 10.3892/br.2021.1449 Abstract. The major constituents of Coffea arabica (coffee), or sucrase‑isomaltase cleaves the α‑glucoside bonds of including caffeine, chlorogenic acid and caffeic acid, exhibit disaccharides, including sucrose, to monosaccharides. The antihyperglycemic properties in in vitro and in vivo models. absorption of dietary monosaccharides by the intestine may However, whether Coffea arabica bean extract (CBE) regu‑ be one of the risk factors associated with diabetes mellitus (1). lates glucose uptake activity and the underlying mechanisms Glucose derived from starch or sucrose is taken up by the involved remain unclear. The aim of the present study was epithelial cells through the brush border membrane (BBM), to examine the effects of CBE on glucose absorption and predominantly by a sodium‑dependent glucose co‑transporter identify the mechanisms involved using an in vitro model. (SGLT1) (2,3). A previous study has revealed that glucose The uptake of a fluorescent glucose analog into Caco‑2 transporter 2 (GLUT2) is expressed at the BBM of enterocytes colorectal adenocarcinoma cells was determined. The expres‑ during the digestive phase and may affect circulatory glucose sion levels of sodium glucose co‑transporter 1 (SGLT1) and concentration (2). Subsequently, glucose effluxes across the baso‑ glucose transporter 2 (GLUT2) were evaluated. -
Transport of Trans-Tiliroside (Kaempferol-3-Β-D-(6''-P-Coumaroyl
This is a repository copy of Transport of trans-tiliroside (kaempferol-3-β-D-(6’’-p-coumaroyl-glucopyranoside) and related flavonoids across Caco-2 cells, as a model of absorption and metabolism in the small intestine. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/84299/ Version: Accepted Version Article: Luo, Z, Morgan, MRA and Day, AJ (2015) Transport of trans-tiliroside (kaempferol-3-β-D-(6’’-p-coumaroyl-glucopyranoside) and related flavonoids across Caco-2 cells, as a model of absorption and metabolism in the small intestine. Xenobiotica: the fate of foreign compounds in biological systems. ISSN 0049-8254 https://doi.org/10.3109/00498254.2015.1007492 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Transport of trans-tiliroside (kaempferol-3--D-(6’’-p-coumaroyl-glucopyranoside) and related flavonoids across Caco-2 cells, as a model of absorption and metabolism in the small intestine Zijun Luo1,2, Michael R.A. -
Brush Border Disaccharidases in Dog Kidney and Their Spatial Relationship to Glucose Transport Receptors
Brush Border Disaccharidases in Dog Kidney and Their Spatial Relationship to Glucose Transport Receptors Melvin Silverman J Clin Invest. 1973;52(10):2486-2494. https://doi.org/10.1172/JCI107439. Research Article The localization of disaccharidases in kidney has been studied by means of the multiple indicator dilution technique. A pulse injection of a solution containing Evans blue dye (plasma marker), creatinine (extracellular marker), and a 14C- labeled disaccharide (lactose, sucrose, maltose, and αα-trehalose), is made into the renal artery of an anesthetized dog, and the outflow curves are monitored simultaneously from renal venous and urine effluents. Lactose and sucrose have an extracellular distribution. Trehalose and maltose remain extracellular from the postglomerular circulation. About 75% of filtered tracer maltose or trehalose is extracted by the luminal surface of the nephron. Thin-layer chromatography of urine samples shows that all of the excreted 14C radiolabel is in the form of the injected disaccharide. Following the administration of phlorizin, all of the filtered radioactivity is recoverable in the urine, but chromatography of the urine samples now reveals that there is a significant excretion of [14C]glucose, approximating the amount previously extracted under control conditions (in the absence of phlorizin). It has been verified that no hydrolysis of maltose or trehalose to their constituent glucose subunits occurred during the transit of tracer between the point of injection (renal artery), and the point of filtration -
Reduction in the Amplitude of Shortening and Ca2+ Transient By
Physiol. Res. 65: 239-250, 2016 https://doi.org/10.33549/physiolres.933045 Reduction in the Amplitude of Shortening and Ca2+ Transient by Phlorizin and Quercetin-3-O-Glucoside in Ventricular Myocytes From Streptozotocin-Induced Diabetic Rats N. N. HAMOUDA1, M. A. QURESHI1, J. M. ALKAABI2, M. OZ1, F. C. HOWARTH1 1Departments of Physiology and Pharmacology, and 2Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, UAE Received March 25, 2015 Accepted June 5, 2015 On-line October 8, 2015 Summary Corresponding author Diabetes mellitus is the leading cause of cardiovascular morbidity C. Howarth, Department of Physiology, College of Medicine and and mortality. Phlorizin (PHLOR) and quercetin-3-O-glucoside Health Sciences, UAE University, P.O. Box 17666, Al Ain, UAE. (QUER-3-G) are two natural compounds reported to have E-mail: [email protected] antidiabetic properties by inhibiting sodium/glucose transporters. Their effects on ventricular myocyte shortening and intracellular Introduction Ca2+ in streptozotocin (STZ)-induced diabetic rats were investigated. Video edge detection and fluorescence photometry Diabetes mellitus (DM) is a major global health were used to measure ventricular myocyte shortening and problem and thirty-five million people with DM live in intracellular Ca2+, respectively. Blood glucose in STZ rats was the Middle East and North Africa. A variety of 4-fold higher (469.64±22.23 mg/dl, n=14) than in Controls complications can arise from uncontrolled DM including (104.06±3.36 mg/dl, n=16). The amplitude of shortening was cardiovascular diseases, neuropathy, nephropathy and reduced by PHLOR in STZ (84.76±2.91 %, n=20) and Control retinopathy which makes it the leading cause of (83.72±2.65 %, n=23) myocytes, and by QUER-3-G in STZ cardiovascular morbidity and mortality, blindness, end- (79.12±2.28 %, n=20) and Control (76.69±1.92 %, n=30) stage renal failure and non-traumatic limb amputations myocytes.